Jan 23 Vertex Pharmaceuticals Inc (VRTX.O) said it will begin late-stage evaluation of telaprevir, the biotechnology company's lead investigational hepatitis C drug, beginning with a key 1050 patient trial.
Vertex is also planning another late-stage trial of the drug in 400 to 500 patients, which will run concurrently with the first.
Final data from both trials is expected in mid-2010, the company said in a news release. (Reporting by Varsha Tickoo in Bangalore)
Our top photos from the past week.